Report on a new ultra-sensitive blood immunoassay that measures a tau tangle biomarker to improve Alzheimer's research monitoring and staging.
Key Takeaways
- Company has launched what it describes as the first commercial blood-based immunoassay for eMTBR-Tau
- It does not mean a simple blood test can now definitively diagnose Alzheimer’s on its own
- Alamar says its NULISA platform can detect eMTBR-Tau at attomolar concentrations